Morphology of coronary atherosclerotic lesions in patie

Nephrology Dialysis Transplantation 15, 218-223 DOI: 10.1093/ndt/15.2.218

Citation Report

#	Article	IF	CITATIONS
2	Microvascular disease—the Cinderella of uraemic heart disease. Nephrology Dialysis Transplantation, 2000, 15, 1493-1503.	0.4	72
3	Electron beam tomography as an endpoint for clinical trials of antiatherosclerotic therapy. Current Atherosclerosis Reports, 2000, 2, 284-289.	2.0	4
5	Renagel®: reducing serum phosphorus in haemodialysis patients. British Journal of Hospital Medicine, 2000, 61, 622-627.	0.3	9
6	Managing phosphate retention: is a change necessary?. Nephrology Dialysis Transplantation, 2000, 15, 1738-1742.	0.4	19
7	Morphology of coronary atherosclerotic lesions in patients with endâ€stage renal failure. Nephrology Dialysis Transplantation, 2000, 15, 1710-1710.	0.4	5
8	Premature cardiovascular disease in chronic renal failure. Lancet, The, 2000, 356, 147-152.	6.3	502
9	Compounds in development to combat hyperphosphataemia. Expert Opinion on Investigational Drugs, 2001, 10, 2185-2190.	1.9	6
10	Mecanismos de desarrollo del daño vascular en pacientes en diálisis. Hipertension Y Riesgo Vascular, 2001, 18, 374-382.	0.3	0
11	Undertreatment of Cardiac Risk Factors in Adolescents with Renal Failure. Peritoneal Dialysis International, 2001, 21, 285-289.	1.1	7
12	Electron Beam Computed Tomography Evaluation of the Rapid Progression of Coronary Artery Calcification in Chronic Hemodialysis Patients. International Journal of Artificial Organs, 2001, 24, 835-837.	0.7	2
13	Dyslipidemia and renal disease: pathogenesis and clinical consequences. Current Opinion in Nephrology and Hypertension, 2001, 10, 195-201.	1.0	68
14	Non-invasive assessments of cardiovascular disease in patients with renal failure. Current Opinion in Nephrology and Hypertension, 2001, 10, 365-369.	1.0	18
15	Control of serum phosphorus: implications for coronary artery calcification and calcific uremic arteriolopathy (calciphylaxis). Current Opinion in Nephrology and Hypertension, 2001, 10, 741-747.	1.0	64
20	Coronary artery disease in uremia: Etiology, diagnosis, and therapy. Kidney International, 2001, 60, 2059-2078.	2.6	91
21	Significant association between the progression of coronary artery calcification and dyslipidemia in patients on chronic hemodialysis. American Journal of Kidney Diseases, 2001, 38, 64-69.	2.1	128
22	Cholesteryl ester transfer protein as a protective factor against vascular disease in hemodialysis patients. American Journal of Kidney Diseases, 2001, 38, 70-76.	2.1	28
23	Setting the stage. American Journal of Kidney Diseases, 2001, 38, S1-S10.	2.1	45
24	GENERAL CARDIOLOGY: Cardiovascular complications of renal disease. British Heart Journal, 2001, 86, 459-466.	2.2	55

#	Article	IF	CITATIONS
25	Independent predictors of restenosis after percutaneous coronary revascularization in haemodialysis patients. Nephrology Dialysis Transplantation, 2001, 16, 2372-2377.	0.4	28
26	How to diagnose and treat coronary artery disease in the uraemic patient: an update. Nephrology Dialysis Transplantation, 2001, 16, 1103-1108.	0.4	14
27	Does calcium kill ESRD patients—the skeptic's perspective. Nephrology Dialysis Transplantation, 2002, 17, 229-232.	0.4	32
28	The Effects of Sevelamer Hydrochloride and Calcium Carbonate on Kidney Calcification in Uremic Rats. Journal of the American Society of Nephrology: JASN, 2002, 13, 2299-2308.	3.0	102
29	Comparison of Dialysis and Clinical Characteristics of Patients with Frequent and Occasional Hemodialysis-Associated Hypotension. Kidney and Blood Pressure Research, 2002, 25, 97-102.	0.9	47
30	Advanced Coronary and Carotid Arteriopathy in Young Adults With Childhood-Onset Chronic Renal Failure. Circulation, 2002, 106, 100-105.	1.6	670
32	Dismal longâ€ŧerm survival of dialysis patients after acute myocardial infarction: can we alter the outcome?. Nephrology Dialysis Transplantation, 2002, 17, 7-10.	0.4	143
33	Cardiac effects of chronic inflammation in dialysis patients. Nephrology Dialysis Transplantation, 2002, 17, 10-15.	0.4	38
34	Progression of vascular calcification in uraemic patients: can it be stopped?. Nephrology Dialysis Transplantation, 2002, 17, 1365-1368.	0.4	19
35	Phosphorus restriction and control of coronary calcification as assessed by electron beam tomography. Current Opinion in Nephrology and Hypertension, 2002, 11, 391-395.	1.0	7
36	Secondary hyperparathyroidism and its therapy as a cardiovascular risk factor among end-stage renal disease patients. Advances in Chronic Kidney Disease, 2002, 9, 193-199.	2.2	15
37	Advanced Oxidation Protein Products, Parathyroid Hormone and Vascular Calcification in Uremia. Blood Purification, 2002, 20, 494-497.	0.9	23
39	Beyond Traditional Risk Factor Analysis for Coronary Artery Disease: The Case for Coronary Artery Calcium Assessment With Electron Beam Computed Tomography. Preventive Cardiology, 2002, 5, 62-67.	1.1	4
40	Effects of excess calcium load on the cardiovascular system measured with electron beam tomography in endâ€stage renal disease. Nephrology Dialysis Transplantation, 2002, 17, 332-335.	0.4	29
41	Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney International, 2002, 62, 245-252.	2.6	1,316
42	Effect of antioxidant therapy with dl-î±-tocopherol on cardiovascular structure in experimental renal failure. Kidney International, 2002, 62, 877-884.	2.6	41
43	Strategies to decrease cardiovascular mortality in patients with end-stage renal disease. Kidney International, 2002, 61, S5-S10.	2.6	16
44	Opinion: How Should Hyperphosphatemia Be Managed in Dialysis Patients?. Seminars in Dialysis, 2002, 15, 315-317.	0.7	18

# 45	ARTICLE Hyperphosphatemia Management. Seminars in Dialysis, 2002, 15, 317-319.	IF 0.7	CITATIONS
46	Hyperphosphatemia Management. Seminars in Dialysis, 2002, 15, 319-321.	0.7	0
47	Hyperphosphatemia Management. Seminars in Dialysis, 2002, 15, 321-324.	0.7	3
48	Hyperphosphatemia Management. Seminars in Dialysis, 2002, 15, 324-326.	0.7	1
49	Hyperphosphatemia Management. Seminars in Dialysis, 2002, 15, 327-328.	0.7	0
50	Calciphylaxis and vascular calcification: a continuum of extra-skeletal osteogenesis. Pediatric Nephrology, 2003, 18, 969-975.	0.9	62
51	Vascular calcification in dialysis patients: Pathogenesis and consequences. American Journal of Kidney Diseases, 2003, 41, S96-S99.	2.1	73
52	Cardiovascular complications in chronic kidney disease. American Journal of Kidney Diseases, 2003, 41, 11-17.	2.1	304
53	The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. American Journal of Kidney Diseases, 2003, 42, 303-309.	2.1	173
54	Coronary artery, aortic wall, and valvular calcification in nondialyzed individuals with type 2 diabetes and renal disease. Kidney International, 2003, 64, 263-271.	2.6	109
55	Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney International, 2003, 64, 1653-1661.	2.6	131
56	Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels. Kidney International, 2003, 64, 1829-1837.	2.6	37
57	Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney International, 2003, 63, 1296-1301.	2.6	144
58	Morphology of the heart and arteries in renal failure. Kidney International, 2003, 63, S80-S83.	2.6	84
59	THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Calcium Phosphate Metabolism and Cardiovascular Disease in Patients with Chronic Kidney Disease. Seminars in Dialysis, 2003, 16, 140-147.	0.7	86
61	Renal Osteodystrophy: Pathogenesis, Diagnosis, and Treatment. , 2003, , 679-701.		9
62	Hyperphosphataemia in Renal Failure. Drugs, 2003, 63, 577-596.	4.9	59
63	Kidney Disease as a Risk Factor for Development of Cardiovascular Disease. Circulation, 2003, 108, 2154-2169.	1.6	3,082

	Сітатіс	on Report	
#	Article	IF	CITATIONS
64	Vascular Calcification in Chronic Renal Failure. Nephron Clinical Practice, 2003, 93, c124-c130.	2.3	34
65	Carotid atherosclerosis in chronic renal failure—the central role of increased plaque burden. Atherosclerosis, 2003, 171, 295-302.	0.4	67
66	Coronary Artery Disease in End-Stage Renal Disease: No Longer a Simple Plumbing Problem. Journal of the American Society of Nephrology: JASN, 2003, 14, 1927-1939.	3.0	208
67	Chronic Renal Failure Accelerates Atherogenesis in Apolipoprotein E–Deficient Mice. Journal of the American Society of Nephrology: JASN, 2003, 14, 2466-2474.	3.0	138
68	Kidney Disease as a Risk Factor for Development of Cardiovascular Disease. Hypertension, 2003, 42, 1050-1065.	1.3	959
69	The Apolipoprotein E Knockout Mouse: A Model Documenting Accelerated Atherogenesis In Uremia. Journal of the American Society of Nephrology: JASN, 2003, 14, 311-316.	3.0	138
70	How to Manage the Renal Patient with Coronary Heart Disease: The Agony and the Ecstasy of Opinion-Based Medicine. Journal of the American Society of Nephrology: JASN, 2003, 14, 2556-2572.	3.0	78
71	Why is coronary heart disease of uraemic patients so frequent and so devastating?. Nephrology Dialysis Transplantation, 2003, 18, 631-640.	0.4	41
72	Musculoskeletal manifestations of chronic renal failure. Current Opinion in Rheumatology, 2003, 15, 48-54.	2.0	65
73	Diagnosis and Therapy of Coronary Artery Disease in Renal Failure, End-Stage Renal Disease, and Renal Transplant Populations. American Journal of the Medical Sciences, 2003, 325, 214-227.	0.4	40
74	Inflammation in Uremic Patients: What Is the Link?. Kidney and Blood Pressure Research, 2003, 26, 65-75.	0.9	15
76	Assessment of Coronary Artery Calcification in Hemodialysis Patients Using Multi-Detector Spiral CT Scan. Hypertension Research, 2004, 27, 527-533.	1.5	92
77	Left Ventricular Hypertrophy Is Associated with Arterial Stiffness and Vascular Calcification in Hemodialysis Patients. Hypertension Research, 2004, 27, 47-52.	1.5	147
79	Calcimimetics and the Treatment of Primary and Secondary Hyperparathyroidism. Annals of Pharmacotherapy, 2004, 38, 1871-1880.	0.9	34
80	Vascular Calcification Mechanisms. Journal of the American Society of Nephrology: JASN, 2004, 15, 2959-2964.	3.0	480
81	Effects of Reduced Dialysate Calcium on Calcium-Phosphorus Product and Bone Metabolism in Hemodialysis Patients. Nephron Clinical Practice, 2004, 96, c3-c9.	2.3	19
82	Increased Expression of Adhesion Molecules in Uremic Atherosclerosis in Apolipoprotein-E-Deficient Mice. Journal of the American Society of Nephrology: JASN, 2004, 15, 1495-1503.	3.0	68
83	Carotid atherosclerosis is a predictor of coronary calcification in chronic haemodialysis patients. Nephrology Dialysis Transplantation, 2004, 19, 885-891.	0.4	33

#	Article	IF	Citations
84	When man turns to stone: Extraosseous calcification in uremic patients. Kidney International, 2004, 65, 2447-2462.	2.6	37
85	Vascular calcification: A stiff challenge for the nephrologist. Kidney International, 2004, 66, 1315-1333.	2.6	140
86	Atherosclerosis and uremic retention solutes. Kidney International, 2004, 66, 1719-1731.	2.6	34
87	Kidney function is inversely associated with coronary artery calcification in men and women free of cardiovascular disease: The Framingham Heart Study. Kidney International, 2004, 66, 2017-2021.	2.6	78
88	Coronary artery calcification measured with electron-beam computerized tomography correlates poorly with coronary artery angiography in dialysis patients. American Journal of Kidney Diseases, 2004, 43, 313-319.	2.1	132
89	Vascular calcification in chronic kidney disease. American Journal of Kidney Diseases, 2004, 43, 572-579.	2.1	381
90	The clinical significance of vascular calcification in young patients with end-stage renal disease. Pediatric Nephrology, 2004, 19, 478-484.	0.9	36
91	Impact of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis. Clinical and Experimental Nephrology, 2004, 8, 54-58.	0.7	225
92	Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scandinavian Journal of Urology and Nephrology, 2004, 38, 405-416.	1.4	114
93	Pathophysiology of Vascular Calcification in Chronic Kidney Disease. Circulation Research, 2004, 95, 560-567.	2.0	440
94	Uremic vasculopathy. Seminars in Nephrology, 2004, 24, 413-416.	0.6	15
95	The renal patient with coronary artery disease. Journal of the American College of Cardiology, 2004, 44, 1343-1353.	1.2	67
96	Homocysteine and carotid intima-media thickness: a critical appraisal of the evidence. Atherosclerosis, 2004, 176, 1-19.	0.4	78
97	Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. American Journal of Kidney Diseases, 2004, 44, 680-688.	2.1	133
98	The renal patient with coronary artery diseaseCurrent concepts and dilemmas. Journal of the American College of Cardiology, 2004, 44, 1343-1353.	1.2	94
99	Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3. Journal of Hypertension, 2005, 23, 1067-1075.	0.3	98
100	Arteriosclerosis, calcium phosphate deposition and cardiovascular disease in uremia: current concepts at the bench. Current Opinion in Nephrology and Hypertension, 2005, 14, 519-524.	1.0	27
101	Cardiac Valvular Calcification as a Marker of Atherosclerosis and Arterial Calcification in End-stage Renal Disease. Archives of Internal Medicine, 2005, 165, 327.	4.3	86

#	Article	IF	CITATIONS
102	Computed tomography coronary calcium screening and myocardial perfusion imaging. Journal of Nuclear Cardiology, 2005, 12, 96-103.	1.4	21
103	Vitamin D analogs down-regulate plasminogen activator inhibitor-1 in human coronary artery smooth muscle cells. Journal of Thrombosis and Haemostasis, 2005, 3, 1545-1546.	1.9	8
104	VITAMIN D IN HEALTH AND DISEASE: The Role of Vitamin D in Vascular Calcification in Chronic Kidney Disease. Seminars in Dialysis, 2005, 18, 307-314.	0.7	50
105	Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney International, 2005, 67, 2295-2304.	2.6	321
106	Pathogenesis of vascular calcification in chronic kidney disease. Kidney International, 2005, 68, 429-436.	2.6	201
107	Vitamin D and its analogues: Do they protect against cardiovascular disease in patients with kidney disease?. Kidney International, 2005, 68, 1973-1981.	2.6	149
108	Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney International, 2005, 68, 2809-2813.	2.6	114
109	Calcification and cardiovascular problems in renal failure. Kidney International, 2005, 67, S120-S127.	2.6	55
110	Dyslipidemia and progression of cardiovascular calcification (CVC) in patients with end-stage renal disease (ESRD). Kidney International, 2005, 67, S43-S50.	2.6	33
111	Left ventricular function and calcium phosphate plasma levels in uraemic patients. Journal of Internal Medicine, 2005, 258, 378-384.	2.7	51
112	Impact of Renal Function on Coronary Plaque Morphology and Morphometry in Patients With Chronic Renal Insufficiency as Determined by Intravascular Ultrasound Volumetric Analysis. American Journal of Cardiology, 2005, 96, 892-896.	0.7	43
113	K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. American Journal of Kidney Diseases, 2005, 45, 16-153.	2.1	543
114	Association Between Carotid Artery Intima-Media Thickness and Cardiovascular Risk Factors in CKD. American Journal of Kidney Diseases, 2005, 46, 856-862.	2.1	76
115	Renal Dysfunction Is a Strong and Independent Risk Factor for Mortality and Cardiovascular Complications in Renal Transplantation. American Journal of Transplantation, 2005, 5, 1986-1991.	2.6	91
116	Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovascular Diabetology, 2005, 4, 4.	2.7	176
117	Strategies for Improving Long-Term Survival in Patients with ESRD. Journal of the American Society of Nephrology: JASN, 2005, 16, S120-S127.	3.0	57
118	Altered Morphologic Properties of Large Arteries in Children with Chronic Renal Failure and after Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2005, 16, 1494-1500.	3.0	246
119	Sevelamer Prevents Uremia-Enhanced Atherosclerosis Progression in Apolipoprotein E–Deficient Mice. Circulation, 2005, 112, 2875-2882.	1.6	139

		CITATION REPO	DRT	
#	Article	I	IF	CITATIONS
120	The severe cardiorenal syndrome: â€~Guyton revisited'. European Heart Journal, 200)5, 26, 11-17.	1.0	415
121	Regulation of Vascular Calcification. Circulation Research, 2005, 96, 717-722.		2.0	270
122	Uremia Accelerates both Atherosclerosis and Arterial Calcification in Apolipoprotein E K Mice. Journal of the American Society of Nephrology: JASN, 2005, 16, 109-116.	nockout	3.0	179
123	Myocardial Stiffness, Cardiac Remodeling, and Diastolic Dysfunction in Calcification-Pro Fetuin-A–Deficient Mice. Journal of the American Society of Nephrology: JASN, 2005,		3.0	119
124	Atherosclerosis and Vascular Calcification in Chronic Renal Failure. Kidney and Blood Pro Research, 2005, 28, 280-289.	essure	0.9	62
125	Calcification of the Coronary Arteries in the Absence of Atherosclerotic Plaque. Mayo C Proceedings, 2005, 80, 807-809.	inic	1.4	10
126	Hyperphosphatemia in Renal Failure. Blood Purification, 2005, 23, 6-9.	(0.9	20
127	Cardiovascular Calcification in End Stage Renal Disease. , 2005, 149, 272-278.			23
128	Atherosclerosis and vascular calcification are independent predictors of left ventricular hypertrophy in chronic haemodialysis patients. Nephrology Dialysis Transplantation, 20	05, 20, 760-767.	0.4	53
129	Calcification of the Coronary Arteries in the Absence of Atherosclerotic Plaque. Mayo C Proceedings, 2005, 80, 807-809.	inic	1.4	11
130	Pathophysiology of Cardiovascular Disease and Renal Failure. Cardiology Clinics, 2005,	23, 311-317.	0.9	18
131	Inflammation and Vascular Calcification. Blood Purification, 2005, 23, 64-71.		0.9	102
132	Biology of Vascular Calcification in Renal Disease. Nephron Experimental Nephrology, 2 e134-e138.	005, 101, :	2.4	16
133	Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenanc patients. American Heart Journal, 2005, 149, 820-825.	e hemodialysis	1.2	225
134	Vascular Calcification in Patients With Renal Failure: Culprit or Innocent Bystander?. Ca Clinics, 2005, 23, 373-384.	rdiology	0.9	11
135	Disordered Mineral Metabolism and Vascular Calcification in Nondialyzed Chronic Kidne Patients. , 2006, 16, 100-118.	y Disease		37
136	Effects of Vitamin D analogs on gene expression profiling in human coronary artery smo cells. Atherosclerosis, 2006, 186, 20-28.	ooth muscle	0.4	152
137	Vascular Calcification in Uremic Conditions: New Insights into Pathogenesis. Seminars i 2006, 26, 33-37.	n Nephrology,	0.6	22

#	Article	IF	CITATIONS
138	Effect of Etidronic Acid on Arterial Calcification in Dialysis Patients. Clinical Drug Investigation, 2006, 26, 215-222.	1.1	61
139	Effects of vitamin D analogs on the expression of plasminogen activator inhibitor-1 in human vascular cells. Thrombosis Research, 2006, 118, 709-714.	0.8	35
140	Phosphate Overload Accelerates Vascular Aging in Uremic Patients. Heart International, 2006, 2, 182618680600200.	0.4	0
141	Uremic Vascular Calcification. Journal of Investigative Medicine, 2006, 54, 380-384.	0.7	24
143	Role of Hyperphosphatemia on Cardiovascular Disease in Dialysis Patients. Vascular Disease Prevention, 2006, 3, 123-128.	0.2	0
144	Hyperphosphatemia and vascular calcification in chronic kidney disease. Therapy: Open Access in Clinical Medicine, 2006, 3, 691-692.	0.2	1
145	Vascular Calcifications in Uremia: Old Concepts and New Insights. Seminars in Dialysis, 2006, 19, 60-68.	0.7	49
146	Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. European Journal of Clinical Investigation, 2006, 36, 51-62.	1.7	114
147	Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International, 2006, 69, 1945-1953.	2.6	1,586
148	Novel insights into vascular calcification. Kidney International, 2006, 70, S5-S9.	2.6	46
148 151	Novel insights into vascular calcification. Kidney International, 2006, 70, S5-S9. Systemic immunosuppressive therapy inhibits in-stent restenosis in patients with renal allograft. Catheterization and Cardiovascular Interventions, 2006, 68, 567-573.	2.6 0.7	46 4
	Systemic immunosuppressive therapy inhibits in-stent restenosis in patients with renal allograft.		
151	Systemic immunosuppressive therapy inhibits in-stent restenosis in patients with renal allograft. Catheterization and Cardiovascular Interventions, 2006, 68, 567-573.	0.7	4
151 152	Systemic immunosuppressive therapy inhibits in-stent restenosis in patients with renal allograft. Catheterization and Cardiovascular Interventions, 2006, 68, 567-573. Vascular Calcification in Patients with Chronic Kidney Disease. Blood Purification, 2006, 24, 56-62. Fetuin-A and kidney function in persons with coronary artery disease—data from the heart and soul	0.7	4 27
151 152 153	Systemic immunosuppressive therapy inhibits in-stent restenosis in patients with renal allograft. Catheterization and Cardiovascular Interventions, 2006, 68, 567-573. Vascular Calcification in Patients with Chronic Kidney Disease. Blood Purification, 2006, 24, 56-62. Fetuin-A and kidney function in persons with coronary artery disease—data from the heart and soul study. Nephrology Dialysis Transplantation, 2006, 21, 2144-2151. Beyond phosphate-role of uraemic toxins in cardiovascular calcification. Nephrology Dialysis	0.7 0.9 0.4	4 27 67
151 152 153 154	Systemic immunosuppressive therapy inhibits in-stent restenosis in patients with renal allograft. Catheterization and Cardiovascular Interventions, 2006, 68, 567-573. Vascular Calcification in Patients with Chronic Kidney Disease. Blood Purification, 2006, 24, 56-62. Fetuin-A and kidney function in persons with coronary artery disease—data from the heart and soul study. Nephrology Dialysis Transplantation, 2006, 21, 2144-2151. Beyond phosphate-role of uraemic toxins in cardiovascular calcification. Nephrology Dialysis Transplantation, 2006, 21, 3354-3357. The treatment of coronary artery disease in patients with chronic kidney disease. QJM - Monthly	0.7 0.9 0.4 0.4	4 27 67 9
151 152 153 154 155	Systemic immunosuppressive therapy inhibits in-stent restenosis in patients with renal allograft. Catheterization and Cardiovascular Interventions, 2006, 68, 567-573. Vascular Calcification in Patients with Chronic Kidney Disease. Blood Purification, 2006, 24, 56-62. Fetuin-A and kidney function in persons with coronary artery disease—data from the heart and soul study. Nephrology Dialysis Transplantation, 2006, 21, 2144-2151. Beyond phosphate-role of uraemic toxins in cardiovascular calcification. Nephrology Dialysis Transplantation, 2006, 21, 3354-3357. The treatment of coronary artery disease in patients with chronic kidney disease. QJM - Monthly Journal of the Association of Physicians, 2006, 99, 723-736. Consequences of Secondary Hyperparathyroidism on Vascular Calcification and Cardiovascular	0.7 0.9 0.4 0.4 0.2	4 27 67 9 34

#	Article	IF	CITATIONS
160	Underrepresentation of Renal Disease in Randomized Controlled Trials of Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2006, 296, 1377.	3.8	353
161	Role of Phosphorus and Vitamin D Analogs in the Pathogenesis of Vascular Calcification. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 90-98.	1.3	77
162	Elevated phosphorus modulates vitamin D receptor-mediated gene expression in human vascular smooth muscle cells. American Journal of Physiology - Renal Physiology, 2007, 293, F1592-F1604.	1.3	22
163	Towards a Better Understanding of Cardiac and Vascular Disease in Patients with Chronic Kidney Disease. Current Cardiology Reviews, 2007, 3, 105-109.	0.6	0
164	Soluble CD154 Is a Unique Predictor of Nonfatal and Fatal Atherothrombotic Events in Patients Who Have End-Stage Renal Disease and Are on Hemodialysis. Journal of the American Society of Nephrology: JASN, 2007, 18, 1323-1330.	3.0	15
165	Detection of coronary and peripheral artery calcification in patients with chronic kidney disease stages 3 and 4, with and without diabetes. Nephrology Dialysis Transplantation, 2007, 22, 3208-3213.	0.4	49
166	Optimising the treatment of hyperphosphatemia and vascular calcification in chronic kidney disease. Expert Opinion on Emerging Drugs, 2007, 12, 341-343.	1.0	3
167	Electron-Beam Computerized Tomography Correlates with Coronary Angiogram in Chronic Kidney Disease Patients. American Journal of Nephrology, 2007, 27, 247-252.	1.4	25
168	Differential Associations of Traditional and Non-Traditional Risk Factors with Carotid Intima-Media Thickening and Plaque in Peritoneal Dialysis Patients. American Journal of Nephrology, 2007, 27, 458-465.	1.4	23
169	Uremia-related vascular calcification: More than apatite deposition. Kidney International, 2007, 71, 298-303.	2.6	78
170	Pulse Wave Velocity Is Inversely Related to Vertebral Bone Density in Hemodialysis Patients. Hypertension, 2007, 49, 1278-1284.	1.3	73
171	The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 766-785.	2.2	30
172	Vitamin D Analogs Modulate the Expression of Plasminogen Activator Inhibitor-1, Thrombospondin-1 and Thrombomodulin in Human Aortic Smooth Muscle Cells. Journal of Vascular Research, 2007, 44, 11-18.	0.6	77
173	Coronary Artery Calcifications: A Critical Assessment of Imaging Techniques. Blood Purification, 2007, 25, 115-119.	0.9	7
174	Calcification of Coronary Intima and Media: Immunohistochemistry, Backscatter Imaging, and X-Ray Analysis in Renal and Nonrenal Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 121-134.	2.2	127
175	Is the anti-inflammatory effect of regular exercise responsible for reduced cardiovascular disease?. Clinical Science, 2007, 112, 543-555.	1.8	99
176	Omega-3 Fatty Acids: from Biochemistry to their Clinical Use in the Prevention of Cardiovascular Disease. Recent Patents on Cardiovascular Drug Discovery, 2007, 2, 13-21.	1.5	35
177	Association of pulse wave velocity with vascular and valvular calcification in hemodialysis patients. Kidney International, 2007, 71, 802-807.	2.6	153

#	Article	IF	CITATIONS
178	Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure. American Heart Journal, 2007, 153, 471-477.	1.2	26
179	CD40–CD154 expression in calcified and non-calcified coronary lesions of patients with chronic renal failure. Atherosclerosis, 2007, 190, 156-166.	0.4	25
180	Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrology Dialysis Transplantation, 2007, 23, 586-593.	0.4	214
181	Chronic Kidney Disease–Mineral-Bone Disorder: A New Paradigm. Advances in Chronic Kidney Disease, 2007, 14, 3-12.	0.6	228
183	Hyperphosphatemia in Dialysis Patients: The Therapeutic Role of Lanthanum Carbonate. International Journal of Artificial Organs, 2007, 30, 293-300.	0.7	14
185	The impact of advanced chronic kidney disease on inâ€hospital mortality following percutaneous coronary intervention for acute myocardial infarction. Catheterization and Cardiovascular Interventions, 2007, 70, 701-705.	0.7	21
186	Vascular calcification and arterial stiffness in chronic kidney disease: Implications and management. Nephrology, 2007, 12, 500-509.	0.7	71
187	VASCULAR CALCIFICATION IN PATIENTS WITH KIDNEY DISEASE: Vascular Calcification and Disordered Mineral Metabolism in Dialysis Patients. Seminars in Dialysis, 2007, 20, 139-143.	0.7	48
188	Effects of Lowering Dialysate Calcium Concentration on Mineral Metabolism and Parathyroid Hormone Secretion: A Multicentric Study. Therapeutic Apheresis and Dialysis, 2007, 11, 121-130.	0.4	19
189	Effect of 2-Methylene-19-nor-(20S)-1α-Hydroxy-Bishomopregnacalciferol (2MbisP), an Analog of Vitamin D, on Secondary Hyperparathyroidism. Journal of Bone and Mineral Research, 2007, 22, 686-694.	3.1	14
190	Coronary revascularization in end-stage renal disease. Current Cardiology Reports, 2007, 9, 389-395.	1.3	6
191	Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. International Urology and Nephrology, 2008, 40, 1075-1082.	0.6	140
192	Poor correlation between coronary artery calcification and obstructive coronary artery disease in an end-stage renal disease patient. Hemodialysis International, 2008, 12, 16-22.	0.4	29
193	Calcification of the internal elastic lamina of coronary arteries. Modern Pathology, 2008, 21, 1019-1028.	2.9	34
194	NON ORONARY HEART DISEASE IN DIALYSIS PATIENTS: Hypertrophy and Fibrosis in the Cardiomyopathy of Uremia—Beyond Coronary Heart Disease. Seminars in Dialysis, 2008, 21, 308-318.	0.7	140
195	A 1-Year Randomized Trial of Calcium Acetate Versus Sevelamer on Progression of Coronary Artery Calcification in Hemodialysis Patients With Comparable Lipid Control: The Calcium Acetate Renagel Evaluation-2 (CARE-2) Study. American Journal of Kidney Diseases, 2008, 51, 952-965.	2.1	291
196	Association of Changes in Bone Remodeling and Coronary Calcification in Hemodialysis Patients: A Prospective Study. American Journal of Kidney Diseases, 2008, 52, 1139-1150.	2.1	112
197	Effect of Simvastatin in Apolipoprotein E Deficient Mice With Surgically Induced Chronic Renal Failure. Journal of Urology, 2008, 179, 1631-1636.	0.2	27

		CITATION REPORT	т
#	ARTICLE Thorax CT Findings in Symptomatic Hemodialysis Patients. Transplantation Proceedings, 2008,	IF 40, 71-76. 0.3	CITATIONS
198	morax er rindings in symptomatic riemodialysis ratients. Hansplantation rioceedings, 2000,	-0,7170. 0.3	7
199	Oxidative stress, phosphate and creatinine levels are independently associated with vascular endothelial growth factor levels in patients with chronic renal failure. Cytokine, 2008, 43, 98-10)1. 1.4	34
200	Differential Effects of Age on Carotid Augmentation Index and Aortic Pulse Wave Velocity in En Renal Disease Patients. Journal of the Chinese Medical Association, 2008, 71, 166-173.	d-stage 0.6	7
201	Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials Atherosclerosis, 2008, 196, 823-834.	;. 0.4	57
202	Amplification of Atherosclerotic Calcification and Mönckeberg's Sclerosis: A Spectrum of the S Disease Process. Advances in Chronic Kidney Disease, 2008, 15, 396-412.	Same 0.6	29
203	Chapter 6 Vascular Calcification Inhibitors In Relation To Cardiovascular Disease With Special Emphasis On Fetuinâ€A In Chronic Kidney Disease. Advances in Clinical Chemistry, 2008, 46, 21	17-262. 1.8	30
204	Media Calcification and Intima Calcification Are Distinct Entities in Chronic Kidney Disease. Clin Journal of the American Society of Nephrology: CJASN, 2008, 3, 1599-1605.	ical 2.2	308
205	Contribution of Bone and Mineral Abnormalities to Cardiovascular Disease in Patients with Chro Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 836-84		71
206	Effects of Sevelamer on the Progression of Vascular Calcification in Patients on Chronic Haemodialysis. Nephron Clinical Practice, 2008, 108, c278-c283.	2.3	59
207	Vascular Calcification and Uremia: What Do We Know?. American Journal of Nephrology, 2008, 339-346.	28, 1.4	72
208	Lipid Abnormalities and Cardiovascular Risk in Renal Disease. Journal of the American Society of Nephrology: JASN, 2008, 19, 1065-1070.	3.0	49
209	Accelerated Atherosclerotic Calcification and Mo[Combining Diaeresis]nckeberg's Sclerosis. Cli Journal of the American Society of Nephrology: CJASN, 2008, 3, 1585-1598.	nical 2.2	160
210	Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease Patient. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 505-521.	2.2	472
211	Diffuse vascular calcification in a dialysis patient. Kidney International, 2008, 73, 890-894.	2.6	1
212	IL-18 is involved in vascular injury in end-stage renal disease patients. Nephrology Dialysis Transplantation, 2008, 24, 589-596.	0.4	37
213	25-Hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients. Nephrology Dialysis Transplantation, 2008, 24, 611-618.	0.4	81
214	Sirolimus-Eluting Stents vs Bare Metal Stents for Coronary Intervention in Japanese Patients Wi Renal Failure on Hemodialysis. Circulation Journal, 2008, 72, 56-60.	th 0.7	96
215	One-Year Clinical Outcomes of Dialysis Patients After Implantation With Sirolimus-Eluting Coro Stents. Circulation Journal, 2008, 72, 1430-1435.	nary 0.7	35

#	Article	IF	CITATIONS
216	Aortic Arch Calcification and Arterial Stiffness are Independent Factors for Diastolic Left Ventricular Dysfunction in Chronic Hemodialysis Patients. Circulation Journal, 2008, 72, 1768-1772.	0.7	52
217	Murine Models of Atherosclerotic Calcification. Current Drug Targets, 2008, 9, 224-228.	1.0	9
218	The mechanisms of hyperphosphatemia-induced vascular calcification. International Journal of Artificial Organs, 2008, 31, 1002-1003.	0.7	14
220	Alteraciones del metabolismo óseo y mineral. , 2009, , 397-435.		Ο
221	A Model on the Induction of Adverse Vascular Long-Term Effects of NSAIDs. Medicinal Chemistry, 2009, 5, 23-28.	0.7	1
222	Validity and Usefulness of Aortic Arch Calcification in Chest X-Ray. Journal of Atherosclerosis and Thrombosis, 2009, 16, 256-264.	0.9	63
223	Arterial and Aortic Valve Calcification Abolished by Elastolytic Cathepsin S Deficiency in Chronic Renal Disease. Circulation, 2009, 119, 1785-1794.	1.6	272
224	Coronary Calcification in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1883-1885.	2.2	7
226	A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia. Kidney International, 2009, 75, 60-71.	2.6	80
227	Expression and Role of the Calcium-Sensing Receptor in the Blood Vessel Wall. Current Pharmaceutical Biotechnology, 2009, 10, 282-288.	0.9	16
228	The emerging role of phosphate in vascular calcification. Kidney International, 2009, 75, 890-897.	2.6	407
229	Vascular Calcification and ESRD. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, S102-S105.	2.2	35
230	Does Vascular Calcification Correlate with Pulse Wave Velocity in Hemodialysis Patients?. Nephrology Research & Reviews, 2009, 1, 11-17.	0.2	3
231	Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities. Kidney International, 2009, 76, S22-S49.	2.6	14
232	Parathyroid hormone decreases endothelial osteoprotegerin secretion: role of protein kinase A and C. American Journal of Physiology - Renal Physiology, 2009, 296, F60-F66.	1.3	17
233	The role of statins in chronic kidney disease (CKD): Friend or foe?. , 2009, 122, 312-323.		20
234	Clinical assessment of atherosclerotic parameters and cardiac function in chronic hemodialysis patients. Clinical and Experimental Nephrology, 2009, 13, 651-658.	0.7	10
235	Synthesis, spectroscopic and structural elucidation of sympathomimetic amine, tyraminium dihydrogenphosphate. Amino Acids, 2009, 36, 185-193.	1.2	14

#	Article	IF	CITATIONS
236	Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatric Nephrology, 2009, 24, 1445-1452.	0.9	237
237	Impact of Chronic Kidney Disease on Early (30-Day) and Late (1-Year) Outcomes of Patients With Acute Coronary Syndromes Treated With Alternative Antithrombotic Treatment Strategies. JACC: Cardiovascular Interventions, 2009, 2, 748-757.	1.1	66
238	Relationship between vascular calcification, arterial stiffness and bone mineral density in a crossâ€sectional study of prevalent Australian haemodialysis patients. Nephrology, 2009, 14, 105-112.	0.7	35
239	Review article: Getting the balance right: Assessing causes and extent of vascular calcification in chronic kidney disease. Nephrology, 2009, 14, 389-394.	0.7	28
240	Associations between vascular calcification, arterial stiffness and bone mineral density in chronic hemodialysis patients. Geriatrics and Gerontology International, 2009, 9, 246-252.	0.7	36
241	Fluctuations of Exercise Capacity in Patients After Kidney Transplantation. Transplantation Proceedings, 2009, 41, 184-187.	0.3	5
242	Prediction of Hemodynamically Significant Coronary Artery Disease Using Troponin I in Hemodialysis Patients Presenting with Chest Pain: A Case-Control Study. Cardiology, 2009, 114, 292-297.	0.6	4
244	Intima-media thickness is a useful marker of the extent of coronary artery disease in patients with impaired renal function. Atherosclerosis, 2009, 202, 470-475.	0.4	29
245	Secondary Prevention in Concurrent Coronary Artery, Cerebrovascular, and Chronic Kidney Disease: Focus on Pharmacological Therapy. Cardiovascular Therapeutics, 2009, 27, 199-215.	1.1	10
246	VASCULAR CALCIFICATION IN CHRONIC KIDNEY DISEASE: A CLINICAL REVIEW. Journal of Renal Care, 2009, 35, 45-50.	0.6	12
247	Prevention of Cardiovascular Disease in Chronic Kidney Disease Patients. Seminars in Nephrology, 2009, 29, 24-29.	0.6	6
248	Vascular Calcification in Chronic Kidney Disease: Pathogenesis and Clinical Implications. , 2009, 19, 78-81.		13
249	Elevated Serum Phosphate Predicts Mortality in Renal Transplant Recipients. Transplantation, 2009, 87, 1040-1044.	0.5	60
250	Clinical Outcomes of Sirolimus-Eluting Stenting After Rotational Atherectomy. Circulation Journal, 2009, 73, 2042-2049.	0.7	33
251	Coagulation Meets Calcification: The Vitamin K System. International Journal of Artificial Organs, 2009, 32, 67-74.	0.7	54
252	Hemodialysis is an Independent Predictor of Coronary In-stent Restenosis after Paclitaxel Eluting Stent Implantation. Internal Medicine, 2010, 49, 2379-2384.	0.3	10
253	Low responsiveness to thienopyridine in hemodialysis patients. Cardiovascular Intervention and Therapeutics, 2010, 25, 18-23.	1.2	4
254	Association of Kidney Function With Coronary Atherosclerosis and Calcification in Autopsy Samples From Japanese Elders: The Hisayama Study. American Journal of Kidney Diseases, 2010, 55, 21-30.	2.1	163

#	Article	IF	CITATIONS
255	Coronary Calcifications: Lessons From Histology in CKD Patients. American Journal of Kidney Diseases, 2010, 55, 1-4.	2.1	93
256	Major Adverse Cardiac Events in Patients With Moderate to Severe Renal Insufficiency Treated With First-Generation Drug-Eluting Stents. American Journal of Cardiology, 2010, 105, 293-296.	0.7	8
257	Measuring Vascular Calcification Clinical Practice. Seminars in Dialysis, 2010, 23, 263-266.	0.7	2
258	Cardiovascular Death in Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 335-340.	2.2	40
259	Vitamin D Receptor Activators Induce an Anticalcific Paracrine Program in Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 321-326.	1.1	37
260	Alterations of Lipid Metabolism in Chronic Nephropathies: Mechanisms, Diagnosis and Treatment. Kidney and Blood Pressure Research, 2010, 33, 100-110.	0.9	32
261	Cardiovascular Disease in Chronic Kidney Disease. , 2010, , 935-950.		4
262	Republished paper: Arterial stiffness in chronic kidney disease: causes and consequences. Postgraduate Medical Journal, 2010, 86, 560-566.	0.9	15
263	The Circulating Inactive Form of Matrix Gla Protein Is a Surrogate Marker for Vascular Calcification in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 568-575.	2.2	251
264	Prevalence and Prognostic Significance of Renal Artery Calcification in Patients with Diabetes and Proteinuria. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2093-2100.	2.2	24
265	Chronic Kidney Disease-Mineral Bone Disorder. , 2010, , 98-114.		5
266	Coronary artery calcification and coronary flow velocity in haemodialysis patients. Nephrology Dialysis Transplantation, 2010, 25, 2685-2690.	0.4	36
267	The five most cited NDT articles from 1999 to 2004. Nephrology Dialysis Transplantation, 2010, 25, 2818-2824.	0.4	1
268	Fetuin-A is an independent determinant of change of aortic stiffness over 1 year in non-diabetic patients with CKD stages 3 and 4. Nephrology Dialysis Transplantation, 2010, 25, 1853-1858.	0.4	52
269	Chronic kidney disease-mineral bone disorder (CKD-MBD). IBMS BoneKEy, 2010, 7, 447-457.	0.1	8
270	The Effect of Sevelamer Hydrochloride and Calcium-Based Phosphate Binders on Mortality in Hemodialysis Patients: A Need for More Research. The Consultant Pharmacist, 2010, 25, 41-54.	0.4	3
271	Arterial stiffness in chronic kidney disease: causes and consequences. Heart, 2010, 96, 817-823.	1.2	124
272	A Preoperative Echocardiographic Predictive Model for Assessment of Cardiovascular Outcome after Renal Transplantation. Journal of the American Society of Echocardiography, 2010, 23, 560-566.	1.2	16

#	Article	IF	CITATIONS
273	Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney International, 2010, 77, 1098-1106.	2.6	357
274	Osteoprotegerin as a Predictor of Coronary Artery Disease and Cardiovascular Mortality and Morbidity. Journal of the American College of Cardiology, 2010, 55, 2049-2061.	1.2	212
275	Atherosclerosis in CKD: differences from the general population. Nature Reviews Nephrology, 2010, 6, 723-735.	4.1	174
276	Coronary artery calcification and mortality in diabetic patients with proteinuria. Kidney International, 2010, 77, 1107-1114.	2.6	78
277	SCREENING FOR CARDIOVASCULAR DISEASE IN PATIENTS WITH ADVANCED CHRONIC KIDNEY DISEASE. Journal of Renal Care, 2010, 36, 68-75.	0.6	7
278	Aortic arch calcification detectable on chest X-ray is a strong independent predictor of cardiovascular events beyond traditional risk factors. Atherosclerosis, 2010, 210, 137-144.	0.4	87
279	Recent progress in the treatment of vascular calcification. Kidney International, 2010, 78, 1232-1239.	2.6	63
280	Sudden cardiac death in chronic kidney disease: epidemiology and prevention. Nature Reviews Nephrology, 2011, 7, 145-154.	4.1	118
281	Noninvasive imaging for assessment of calcification in chronic kidney disease. Nature Reviews Nephrology, 2011, 7, 567-577.	4.1	54
282	Epicardial Adipose Tissue and Coronary Artery Calcification in Diabetic and Nondiabetic End-Stage Renal Disease Patients. Renal Failure, 2011, 33, 770-775.	0.8	28
283	Medial or intimal calcification in CKD—does it matter?. Nature Reviews Nephrology, 2011, 7, 250-251.	4.1	8
284	Current developments in lipid-lowering therapy for the patient with chronic kidney disease. Clinical Lipidology, 2011, 6, 693-702.	0.4	0
285	Mineral-bone metabolism markers in young hemodialysis patients. Clinical Biochemistry, 2011, 44, 1425-1428.	0.8	12
286	Risk factors and metabolic mechanisms in the pathogenesis of uraemic cardiac disease. Frontiers in Bioscience - Landmark, 2011, 16, 1364.	3.0	20
287	Animal Models of Calcific Aortic Valve Disease. International Journal of Inflammation, 2011, 2011, 1-18.	0.9	94
288	Complications and Managements of Hyperphosphatemia in Dialysis. , 2011, , .		0
289	Comparison of haemodialysis patients and non-haemodialysis patients with respect to clinical characteristics and 3-year clinical outcomes after sirolimus-eluting stent implantation: insights from the Japan multi-centre post-marketing surveillance registry. European Heart Journal, 2011, 32, 829-837.	1.0	50
290	Potential Role of Recombinant Erythropoietin and Intravenous Iron Preparations in Target Vessel Re-Stenosis Following Coronary Stint Insertions in Hemodialysis Patients. Internal Medicine, 2011, 50, 1449-1450.	0.3	0

#	Article	IF	CITATIONS
291	The Authors Reply: Potential Role of Recombinant Erythropoietin and Intravenous Iron Preparations in Target Vessel Re-Stenosis Following Coronary Stint Insertions in Hemodialysis Patients. Internal Medicine, 2011, 50, 1447-1447.	0.3	0
292	Impact of Diabetes on Cardiovascular Outcomes in Hemodialysis Patients Undergoing Coronary Revascularization. Circulation Journal, 2011, 75, 1616-1625.	0.7	19
293	Management of Coronary Artery Disease in End‣tage Renal Disease. Seminars in Dialysis, 2011, 24, 525-532.	0.7	1
294	Coronary Plaque Morphology Using Virtual Histology–Intravascular Ultrasound Analysis in Hemodialysis Patients. Therapeutic Apheresis and Dialysis, 2011, 15, 44-50.	0.4	20
295	Relationship between renal function stage and clinical outcomes after paclitaxel-eluting stent implantation. Journal of Cardiology, 2011, 57, 61-68.	0.8	15
296	Impact of CKD on Coronary Artery Calcifications. American Journal of Kidney Diseases, 2011, 58, 503-505.	2.1	1
297	Non-invasive risk assessment in patients with chronic kidney disease. Journal of Nuclear Cardiology, 2011, 18, 472-485.	1.4	4
298	Angiographic and clinical outcomes of 100 consecutive severe calcified lesions requiring rotational atherectomy prior to sirolimus-eluting stent implantation in hemodialysis and non-hemodialysis patients. Cardiovascular Intervention and Therapeutics, 2011, 26, 98-103.	1.2	12
299	Importance of measuring the fractional flow reserve in patients receiving hemodialysis. Cardiovascular Intervention and Therapeutics, 2011, 26, 215-221.	1.2	10
300	Carotid artery calcification at the initiation of hemodialysis is a risk factor for cardiovascular events in patients with end-stage renal disease: a cohort study. BMC Nephrology, 2011, 12, 56.	0.8	13
301	Serum Fetuin-A Levels Are Associated with Vascular Calcifications and Predict Cardiovascular Events in Renal Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 974-985.	2.2	57
302	The Relationship Between Chronic Kidney Disease and SYNTAX Score. Angiology, 2011, 62, 504-508.	0.8	44
303	Low iPTH Can Predict Vascular and Coronary Calcifications in Patients Undergoing Peritoneal Dialysis. Nephron Clinical Practice, 2011, 117, c113-c119.	2.3	11
304	Does Uremia Cause Vascular Dysfunction. Kidney and Blood Pressure Research, 2011, 34, 284-290.	0.9	122
305	Increased Calcification and Protein Nitration in Arteries of Chronic Kidney Disease Patients. Blood Purification, 2011, 32, 296-302.	0.9	17
306	Uremic Cardiomyopathy and Insulin Resistance. Journal of the American Society of Nephrology: JASN, 2011, 22, 207-215.	3.0	57
307	Vascular Calcification in Chronic Renal Failure. Circulation Research, 2011, 108, 249-264.	2.0	89
308	Cardiorenal Syndrome Type 4—Cardiovascular Disease in Patients with Chronic Kidney Disease: Epidemiology, Pathogenesis, and Management. International Journal of Nephrology, 2011, 2011, 1-8.	0.7	24

ARTICLE IF CITATIONS The Phosphorus and the Vascular Calcification in ESRD between Old Adventures and New Horizons. 309 0.7 0 International Journal of Nephrology, 2011, 2011, 1-1. Association of Serum Phosphate and Related Factors in ESRD-Related Vascular Calcification. International Journal of Nephrology, 2011, 2011, 1-8. 311 Calcitriol and Analogs in the Treatment of Chronic Kidney Disease., 2011, 1555-1565. 0 Vascular calcification and hypertension: Cause and effect. Annals of Medicine, 2012, 44, S85-S92. Composition and plaque patterns of coronary culprit lesions and clinical characteristics of patients 313 2.6 57 with chronic kidney disease. Kidney International, 2012, 82, 344-351. Chronic Inflammation and Coronary Atherosclerosis in Patients with End-Stage Renal Disease. CardioRenal Medicine, 2012, 2, 117-124. Cardiac Findings at Necropsy in Patients With Chronic Kidney Disease Maintained on Chronic 315 0.4 13 Hemodialysis. Medicine (United States), 2012, 91, 165-178. Bidirectional Nature of Cardiovascular and Kidney Disease. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2012, 12, 168-182. Risk Factors Associated with Coronary Artery Calcification Should Be Examined before Kidney 318 0.5 5 Transplantation. Tohoku Journal of Experimental Medicine, 2012, 226, 137-144. Impacts of estimated glomerular filtration rate on coronary atherosclerosis and plaque composition before and during statin therapy in patients with normal to mild renal dysfunction: Subanalysis of the TRUTH study. Nephrology, 2012, 17, 628-635. Diseases of the Parathyroid Glands., 2012,,. 320 4 Cardiac Catheterization in the Dialysis Population in 2012: We Know More, but Much Remains Unknown. Seminars in Dialysis, 2012, 25, 257-262. Chronic kidney disease–mineral bone disorders in diabetic kidney disease. Clinical Queries Nephrology, 322 0.2 0 2012, 1, 134-137. Pre-transplant cardiac evaluation and management of diabetic kidney disease patients before 0.2 transplant. Clinical Queries Nephrology, 2012, 1, 151-156. Coronary Vascular Dysfunction and Prognosis in Patients With Chronic Kidney Disease. JACC: 324 2.3113 Cardiovascular Imaging, 2012, 5, 1025-1034. Calcific Uremic Arteriolopathy (Calciphylaxis)., 2012, , 113-146. Chronic Kidney Disease-Mineral Bone Disorder: Definitions and Rationale for a Systemic Disorder. 326 1.33 Clinical Reviews in Bone and Mineral Metabolism, 2012, 10, 119-127. Saphenous vein aorto-coronary graft atherosclerosis in patients with chronic kidney disease: more plaque calcification and necrosis, but less vasoconstrictor potential. Basic Research in Cardiology, 19 2012, 107, 303.

#	Article	IF	CITATIONS
328	Experimental research Effect of experimentally induced metabolic acidosis on aortic endothelial permeability and serum nitric oxide concentration in normal and high-cholesterol fed rabbits. Archives of Medical Science, 2012, 4, 719-723.	0.4	5
329	Vascular Calcification: Pathophysiology and Risk Factors. Current Hypertension Reports, 2012, 14, 228-237.	1.5	150
330	Vitamin D and Stage 5 Chronic Kidney Disease: A New Paradigm?. Seminars in Dialysis, 2012, 25, 50-58.	0.7	12
331	Thrombosis of Tunneledâ€Cuffed Hemodialysis Catheters: Treatment With Highâ€Dose Urokinase Lock Therapy. Artificial Organs, 2012, 36, 21-28.	1.0	20
332	Progression of Coronary Artery Calcification and Thoracic Aorta Calcification in Kidney Transplant Recipients. American Journal of Kidney Diseases, 2012, 59, 258-269.	2.1	98
333	Imbalanced Matrix Metalloproteinases in Cardiovascular Complications of Endâ€Stage Kidney Disease: A Potential Pharmacological Target. Basic and Clinical Pharmacology and Toxicology, 2012, 110, 409-415.	1.2	16
334	Sirolimus-eluting stents versus paclitaxel-eluting stents for coronary intervention in patients with renal failure on hemodialysis. Cardiovascular Intervention and Therapeutics, 2013, 28, 9-15.	1.2	9
335	Chronic Kidney Disease as a Coronary Artery Disease Risk Equivalent. Current Cardiology Reports, 2013, 15, 340.	1.3	120
336	Elevated Serum Bone Morphogenetic Protein 4 in Patients with Chronic Kidney Disease and Coronary Artery Disease. Journal of Cardiovascular Translational Research, 2013, 6, 232-238.	1.1	13
337	Altered Lipid Metabolism and Serum Lipids in Kidney Disease and Kidney Failure. , 2013, , 31-48.		1
338	Biochemical markers of vascular calcification in elderly hemodialysis patients. Molecular and Cellular Biochemistry, 2013, 374, 21-27.	1.4	22
339	Cost-Effectiveness of Statins for Primary Cardiovascular Prevention in Chronic Kidney Disease. Journal of the American College of Cardiology, 2013, 61, 1250-1258.	1.2	47
340	Clinical Detection, Risk Factors, and Cardiovascular Consequences of Medial Arterial Calcification: A Pattern of Vascular Injury Associated With Aberrant Mineral Metabolism. Seminars in Nephrology, 2013, 33, 93-105.	0.6	45
341	Calcium, Phosphate, PTH, Vitamin D and FGF-23 in Chronic Kidney Disease. , 2013, , 263-283.		2
342	Arterial disease in chronic kidney disease. Heart, 2013, 99, 365-372.	1.2	119
343	KardiovaskulÃæ Verkalkungen im Rahmen des chronischen kardiorenalen Syndroms: welche Bedeutung haben Biomarker für Diagnostik und Risikostratifizierung?. Laboratoriums Medizin, 2013, 37, 199-208.	0.1	0
344	Long-Term Survival and Repeat Coronary Revascularization in Dialysis Patients After Surgical and Percutaneous Coronary Revascularization With Drug-Eluting and Bare Metal Stents in the United States. Circulation, 2013, 127, 1861-1869.	1.6	95
345	Nonthyroidal illness: a risk factor for coronary calcification and arterial stiffness in patients undergoing peritoneal dialysis?. Journal of Internal Medicine, 2013, 274, 584-593.	2.7	34

#	Article	IF	CITATIONS
346	Chronic kidney disease is associated with neovascularization and intraplaque hemorrhage in coronary atherosclerosis in elders: results from the Hisayama Study. Kidney International, 2013, 84, 373-380.	2.6	34
347	Cardiovascular Disease in Hemodialysis Patients. , 0, , .		1
348	Association Between Renal Vasculature Changes and Generalized Atherosclerosis: An Autopsy Survey. Journal of Atherosclerosis and Thrombosis, 2014, 21, 99-107.	0.9	6
349	Circulating Endothelial Cells and Chronic Kidney Disease. BioMed Research International, 2014, 2014, 1-7.	0.9	7
350	Pravastatin and Olmesartan Synergistically Ameliorate Renal Failure-Induced Vascular Calcification. Journal of Atherosclerosis and Thrombosis, 2014, 21, 917-929.	0.9	23
351	How do We Manage Coronary Artery Disease in Patients with CKD and ESRD?. Electrolyte and Blood Pressure, 2014, 12, 41.	0.6	15
352	Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs. World Journal of Nephrology, 2014, 3, 156.	0.8	79
353	ARTERIAL STIFFNESS AND CHRONIC KIDNEY DISEASE: CAUSES AND CONSEQUENCES. Rational Pharmacotherapy in Cardiology, 2014, 10, 83-91.	0.3	4
354	Pattern and correlates of cardiac lesions in a group of sub-Saharan African patientson maintenance hemodialysis. Pan African Medical Journal, 2014, 17, 3.	0.3	17
355	Calcification of the Internal Pudendal Artery and Development of Erectile Dysfunction in Adenine-Induced Chronic Kidney Disease: A Sentinel of Systemic Vascular Changes. Journal of Sexual Medicine, 2014, 11, 2449-2465.	0.3	8
356	Coronary Artery Bypass Grafting Versus Drug-Eluting Stents in Patients with End-Stage Renal Disease. Journal of Cardiac Surgery, 2014, 29, 163-169.	0.3	2
357	Renal function, uraemia and early arteriovenous fistula failure. BMC Nephrology, 2014, 15, 179.	0.8	19
358	Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease. Clinical and Experimental Nephrology, 2014, 18, 265-268.	0.7	70
359	Metabolic syndrome in children with chronic kidney disease and after renal transplantation. Pediatric Nephrology, 2014, 29, 203-216.	0.9	26
360	Is residual renal function and better phosphate control in peritoneal dialysis an answer for the lower prevalence of valve calcification compared to hemodialysis patients?. International Urology and Nephrology, 2014, 46, 175-182.	0.6	29
361	Cardiorenal syndrome—current understanding and future perspectives. Nature Reviews Nephrology, 2014, 10, 48-55.	4.1	114
363	Cardiovascular disease in chronic kidney disease. Clinical Queries Nephrology, 2014, 3, 20-29.	0.2	3
364	Medial vascular calcification revisited: review and perspectives. European Heart Journal, 2014, 35, 1515-1525	1.0	567

#	Article	IF	CITATIONS
365	The Management of Acute Coronary Syndromes in Patients With Chronic Kidney Disease. Advances in Chronic Kidney Disease, 2014, 21, 472-479.	0.6	7
366	Screening and Risk Stratification ofÂCoronary Artery Disease in End-Stage Renal Disease. JACC: Cardiovascular Imaging, 2014, 7, 715-728.	2.3	55
367	Statins in chronic kidney disease and kidney transplantation. Pharmacological Research, 2014, 88, 62-73.	3.1	22
368	Activation of Nrf2 by dimethyl fumarate improves vascular calcification. Vascular Pharmacology, 2014, 63, 29-36.	1.0	61
369	Usefulness of serum interleukin-18 in predicting cardiovascular mortality in patients with chronic kidney disease – systems and clinical approach. Scientific Reports, 2015, 5, 18332.	1.6	42
370	Pitavastatin Reduces Inflammation in Atherosclerotic Plaques in Apolipoprotein E-Deficient Mice with Late Stage Renal Disease. PLoS ONE, 2015, 10, e0138047.	1.1	13
371	The prevalence of vascular calcification in patients with end-stage renal disease on hemodialysis: a cross-sectional observational study. Therapeutic Advances in Chronic Disease, 2015, 6, 84-96.	1.1	46
372	The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 791-799.	2.2	75
373	Elevation of Interleukin-18 Correlates With Cardiovascular, Cerebrovascular, and Peripheral Vascular Events. Medicine (United States), 2015, 94, e1836.	0.4	9
374	Clinical Outcomes of Treatment by Percutaneous Coronary Intervention Versus Coronary Artery Bypass Graft Surgery in Patients With Chronic Kidney Disease Undergoing Index Revascularization in Ontario. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	42
375	Membrane-bound Klotho is not expressed endogenously in healthy or uraemic human vascular tissue. Cardiovascular Research, 2015, 108, 220-231.	1.8	42
376	Coronary plaque progression of non-culprit lesions after culprit percutaneous coronary intervention in patients with moderate to advanced chronic kidney disease: intravascular ultrasound and integrated backscatter intravascular ultrasound study. International Journal of Cardiovascular Imaging. 2015. 31. 935-945.	0.7	19
377	The Effect of n-3 Fatty Acids on Small Dense Low-Density Lipoproteins in Patients With End-Stage Renal Disease: A Randomized Placebo-Controlled Intervention Study. , 2015, 25, 376-380.		12
378	Arterial Disorders. , 2015, , .		2
379	Pathophysiology of Vascular Calcification. Current Osteoporosis Reports, 2015, 13, 372-380.	1.5	83
380	Correlation between indices of kidney function (estimated Glomerular Filteration Rate and) Tj ETQq1 1 0.784314 2015, 67, 21-26.	rgBT /Ove 0.4	rlock 10 T O
382	The Association of Calcium-Phosphorus Product With the Severity of Cardiac Valves Failure in Patients Under Chronic Hemodialysis. Cardiology Research, 2016, 7, 80-83.	0.5	12
383	Imaging of coronary atherosclerosis in various susceptible groups. Cardiovascular Diagnosis and Therapy, 2016, 6, 382-395.	0.7	13

# 384	ARTICLE Diagnostic and Prognostic Role of Myocardial Perfusion Scintigraphy in Kidney Transplant	IF 0.4	CITATIONS
385	Candidates: Narrative Review. Heart International, 2016, 11, heartint.500023. Matrix Metalloproteinases and Subclinical Atherosclerosis in Chronic Kidney Disease: A Systematic Review. International Journal of Nephrology, 2016, 2016, 1-11.	0.7	22
386	Greater Volume but not Higher Density of Abdominal Aortic Calcium Is Associated With Increased Cardiovascular Disease Risk. Circulation: Cardiovascular Imaging, 2016, 9, .	1.3	17
387	Coronary artery calcium density for the prediction of mortality in CKD patients: One size does not fit all. Atherosclerosis, 2016, 250, 180-182.	0.4	1
388	The heart and vascular system in dialysis. Lancet, The, 2016, 388, 276-284.	6.3	219
389	Long-term risks for patency loss in patients with hemodialysis after bare self-expandable nitinol stent implantation to femoropopliteal artery occlusive lesions. International Journal of Cardiology, 2016, 223, 268-275.	0.8	4
390	p-Cresyl sulfate promotes the formation of atherosclerotic lesions and induces plaque instability by targeting vascular smooth muscle cells. Frontiers of Medicine, 2016, 10, 320-329.	1.5	22
391	Predictors of atherosclerotic events in patients on haemodialysis: post hoc analyses from the AURORA study. Nephrology Dialysis Transplantation, 2016, 33, gfw360.	0.4	14
392	Prognostic utility of negative stress/rest myocardial SPECT studies among patients with different clinical categories of chronic kidney disease: Data from an Egyptian cohort. Egyptian Heart Journal, 2016, 68, 187-192.	0.4	0
393	The Impact of Donor and Recipient Renal Dysfunction on Cardiac Allograft Survival: Insights Into Reno-Cardiac Interactions. Journal of Cardiac Failure, 2016, 22, 368-375.	0.7	11
394	Comparison of longâ€ŧerm patency after endovascular therapy for superficial femoral artery occlusive disease between patients with and without hemodialysis. Catheterization and Cardiovascular Interventions, 2016, 87, 1142-1148.	0.7	5
395	Impact of acute coronary syndromes on survival of dialysis patients following surgical or percutaneous coronary revascularization in the United States. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 205-213.	0.4	16
397	Impact of non-invasive cardiovascular screening programs as a predictor of cardiovascular events among asymptomatic chronic kidney disease patients. Clinical and Experimental Nephrology, 2016, 20, 416-424.	0.7	4
398	Influence of hemodialysis duration on mid-term clinical outcomes in hemodialysis patients with coronary artery disease after drug-eluting stent implantation. Heart and Vessels, 2016, 31, 330-340.	0.5	2
399	The vulnerable patient with chronic kidney disease. Nephrology Dialysis Transplantation, 2016, 31, 382-390.	0.4	33
400	Vascular inflammation and media calcification are already present in early stages of chronic kidney disease. Cardiovascular Pathology, 2017, 27, 57-67.	0.7	45
401	Cardiovascular impact in patients undergoing maintenance hemodialysis: Clinical management considerations. International Journal of Cardiology, 2017, 232, 12-23.	0.8	64
402	The Role of Emerging Risk Factors in Cardiovascular Outcomes. Current Atherosclerosis Reports, 2017, 19, 28.	2.0	43

#	Article	IF	CITATIONS
403	Development of a novel chronic kidney disease mouse model to evaluate the progression of hyperphosphatemia and associated mineral bone disease. Scientific Reports, 2017, 7, 2233.	1.6	47
404	Coronary Plaque Characteristics in Hemodialysis-Dependent Patients as Assessed by OpticalÂCoherence Tomography. American Journal of Cardiology, 2017, 119, 1313-1319.	0.7	19
405	Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: aÂreview. Kidney International, 2017, 91, 797-807.	2.6	102
406	Impact of Hemodialysis on Procedural Outcomes of Percutaneous Coronary Intervention for Chronic Total Occlusion: Insights From the Japanese Multicenter Registry. Journal of the American Heart Association, 2017, 6, .	1.6	6
407	Arterioesclerosis de Mönckeberg. FMC Formacion Medica Continuada En Atencion Primaria, 2017, 24, 416-417.	0.0	0
408	Cardiac Assessment of Patients With Type 1 Diabetes Median 10 Years After Successful Simultaneous Pancreas and Kidney Transplantation Compared With Living Donor Kidney Transplantation. Transplantation, 2017, 101, 1261-1267.	0.5	7
409	Endothelium-Dependent and -Independent Vascular Function in Advanced Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1588-1594.	2.2	45
410	Arterial calcification: A new perspective?. International Journal of Cardiology, 2017, 228, 11-22.	0.8	41
411	Relation Between Renal Function and Coronary Plaque Morphology (from the Assessment of Dual) Tj ETQq0 0 0 American Journal of Cardiology, 2017, 119, 217-224.	rgBT /Ove 0.7	rlock 10 Tf 50 4
412	Higher Serum Levels of Osteoglycin Are Associated with All-Cause Mortality and Cardiovascular and Cerebrovascular Events in Patients with Advanced Chronic Kidney Disease. Tohoku Journal of Experimental Medicine, 2017, 242, 281-290.	0.5	10
413	The Relationship between Carotid and Femoral Artery Intima-Media Thickness and Histopathologic Grade of Atherosclerosis in Patients with Chronic Kidney Disease. Nephron, 2018, 139, 159-169.	0.9	4
414	Compositional Analysis of Coronary Artery Calcification in Dialysis Patients in vivo by Dualâ€Energy Computed Tomography Angiography. Therapeutic Apheresis and Dialysis, 2018, 22, 365-370.	0.4	24
415	Aortic bypass surgery for asymptomatic patients awaiting a kidney transplant: A word of caution. Clinical Transplantation, 2018, 32, e13218.	0.8	9
416	Tumour necrosis factor-alpha in uraemic serum promotes osteoblastic transition and calcification of vascular smooth muscle cells via extracellular signal-regulated kinases and activator protein 1/c-FOS-mediated induction of interleukin 6 expression. Nephrology Dialysis Transplantation, 2018, 33, 574-585.	0.4	56
417	Drug-Eluting Stents Versus Bare-Metal Stents in Patients With End-Stage Renal Disease. American Journal of the Medical Sciences, 2018, 355, 331-341.	0.4	0
418	Impact of stent type and prolonged dual antiplatelet therapy on long-term clinical outcomes in hemodialysis patients with coronary artery disease. Cardiovascular Intervention and Therapeutics, 2018, 33, 84-94.	1.2	8
419	Vascular ossification: Pathology, mechanisms, and clinical implications. Bone, 2018, 109, 28-34.	1.4	35
420	Chronic Kidney Disease as a Risk Factor for Cardiovascular Disease. , 2018, , 600-608.		1

#	Article	lF	CITATIONS
421	OBSOLETE: Chronic Kidney Disease as a Risk Factor for Cardiovascular Disease. , 2018, , .		0
422	Vascular calcification and left ventricular hypertrophy in hemodialysis patients: interrelationship and clinical impacts. International Journal of Medical Sciences, 2018, 15, 557-563.	1.1	14
423	Vascular Calcification in Chronic Kidney Disease: The Role of Inflammation. International Journal of Nephrology, 2018, 2018, 1-7.	0.7	42
424	Phenotypic Modulation of Cultured Primary Human Aortic Vascular Smooth Muscle Cells by Uremic Serum. Frontiers in Physiology, 2018, 9, 89.	1.3	20
425	Relationship between left main and left anterior descending arteries bifurcation angle and coronary artery calcium score in chronic kidney disease: A 3-dimensional analysis of coronary computed tomography. PLoS ONE, 2018, 13, e0198566.	1.1	6
426	Mechanisms of cardiovascular complications in chronic kidney disease: research focus of the Transregional Research Consortium SFB TRR219 of the University Hospital Aachen (RWTH) and the Saarland University. Clinical Research in Cardiology, 2018, 107, 120-126.	1.5	25
427	Identification of differential gene expression patterns in human arteries from patients with chronic kidney disease. American Journal of Physiology - Renal Physiology, 2018, 314, F1117-F1128.	1.3	7
428	Calcitriol and Analogs in the Treatment of Chronic Kidney Disease. , 2018, , 471-484.		0
429	Atherosclerosis in Chronic Kidney Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1938-1966.	1.1	164
430	Associations of left ventricular systolic dysfunction with the factors among Thai patients on peritoneal dialysis: a cross-sectional study. BMC Nephrology, 2019, 20, 257.	0.8	6
431	FGF23 in hemodialysis patients is associated with left ventricular hypertrophy and reduced ejection fraction. Nefrologia, 2019, 39, 258-268.	0.2	3
432	Revascularization Strategies in Patients with Chronic Kidney Disease and Acute Coronary Syndromes. Current Cardiology Reports, 2019, 21, 113.	1.3	1
433	Chronic Kidney Disease and CoronaryÂArtery Disease. Journal of the American College of Cardiology, 2019, 74, 1823-1838.	1.2	403
434	The assessment of coronary artery disease in patients with end-stage renal disease. CKJ: Clinical Kidney Journal, 2019, 12, 721-734.	1.4	19
435	The Cardiorenal Axis: Myocardial Perfusion, Metabolism, and Innervation. Current Cardiology Reports, 2019, 21, 60.	1.3	9
436	Coronary Revascularization in Patients With Advanced Chronic Kidney Disease. Canadian Journal of Cardiology, 2019, 35, 1002-1014.	0.8	7
437	Long-Term Clinical Outcome of Drug-Eluting vs. Bare-Metal Stent Implantation After Percutaneous Coronary Intervention in End-Stage Renal Disease Patients on Hemodialysis ― Nationwide Cohort Study in Taiwan ―. Circulation Journal, 2019, 83, 1239-1246.	0.7	0
438	FCF23 in hemodialysis patients is associated with left ventricular hypertrophy and reduced ejection fraction. Nefrologia, 2019, 39, 258-268.	0.2	8

		CITATION REPORT		
#	Article		IF	CITATIONS
439	Diagnostic Tests for Vascular Calcification. Advances in Chronic Kidney Disease, 2019,	26, 445-463.	0.6	23
440	The Role of Vitamin K in Vascular Calcification. Advances in Chronic Kidney Disease, 20)19, 26, 437-444.	0.6	33
441	Inflammation in Chronic Kidney Disease. , 2019, , 208-223.e9.			0
442	Mineral Bone Disorders in Chronic Kidney Disease. , 2019, , 145-161.e6.			0
443	The Role of the Chronic Kidney Disease Clinic and Multidisciplinary Team Care. , 2019,	, 121-135.e6.		1
444	Vascular age is associated with the risk of dialysis or death in chronic kidney disease. N 2020, 25, 314-322.	lephrology,	0.7	7
445	Cardiovascular Disease and Chronic Kidney Disease. , 2020, , 337-353.			0
446	Renal osteodystrophy and chronic kidney diseaseâ \in "mineral bone disorder. , 2020, , 1-	463-1487.		0
447	Lipid-modifying therapy in chronic kidney disease: Pathophysiological and clinical cons 2020, 207, 107459.	iderations. ,		7
448	An optical coherence tomography comparison of coronary arterial plaque calcification with end-stage renal disease and diabetes mellitus. Diabetes and Vascular Disease Reso 147916412095842.	in patients earch, 2020, 17,	0.9	2
449	[⁶⁸ Ga]Ga-THP-Pam: A Bisphosphonate PET Tracer with Facile Radiolabelir Calcium Mineral Affinity. Bioconjugate Chemistry, 2021, 32, 1276-1289.	ıg and Broad	1.8	17
450	Cardiac Imaging in Dialysis Patients. Kidney Medicine, 2020, 2, 629-638.		1.0	6
451	Oxidative Stress in ESRD Patients on Dialysis and the Risk of Cardiovascular Diseases. 2020, 9, 1079.	Antioxidants,	2.2	28
452	Coronary Artery Disease in patients with Endâ€Stage Kidney Disease; Current perspec knowledge. Seminars in Dialysis, 2020, 33, 187-197.	tive and gaps of	0.7	6
453	Current Therapy in CKD Patients Can Affect Vitamin K Status. Nutrients, 2020, 12, 160)9.	1.7	11
454	Implications of Kidney Disease in the Cardiac Patient. Interventional Cardiology Clinics 265-278.	, 2020, 9,	0.2	2
455	Myostatin in the Arterial Wall of Patients with End-Stage Renal Disease. Journal of Athe and Thrombosis, 2020, 27, 1039-1052.	Prosclerosis	0.9	8
456	Coronary artery calcium burden, carotid atherosclerotic plaque burden, and myocardia in patients with end-stage renal disease: A non-invasive imaging study combining PET/ ultrasound. Journal of Nuclear Cardiology, 2021, 28, 2660-2670.		1.4	6

#	Article	IF	CITATIONS
457	Diagnosis and Management of Pulmonary Hypertension in Patients With CKD. American Journal of Kidney Diseases, 2020, 75, 935-945.	2.1	25
458	Should We Consider the Cardiovascular System While Evaluating CKD-MBD?. Toxins, 2020, 12, 140.	1.5	7
459	Breaking the deadlock of calcified coronary artery lesions: A contemporary review. Catheterization and Cardiovascular Interventions, 2021, 97, 108-120.	0.7	17
460	Vascular pathologies in chronic kidney disease: pathophysiological mechanisms and novel therapeutic approaches. Journal of Molecular Medicine, 2021, 99, 335-348.	1.7	83
461	GSTM1 Modulates Expression of Endothelial Adhesion Molecules in Uremic Milieu. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-12.	1.9	5
462	The cardiovascular–dialysis nexus: the transition to dialysis is a treacherous time for the heart. European Heart Journal, 2021, 42, 1244-1253.	1.0	14
463	Effects of chronic kidney disease and declining renal function on coronary atherosclerotic plaque progression: a PARADIGM substudy. European Heart Journal Cardiovascular Imaging, 2021, 22, 1072-1082.	0.5	8
464	Calcium Modification Techniques in Complex Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2021, 14, e009870.	1.4	16
465	Proteomic Profiling of Leukocytes Reveals Dysregulation of Adhesion and Integrin Proteins in Chronic Kidney Disease-Related Atherosclerosis. Journal of Proteome Research, 2021, 20, 3053-3067.	1.8	5
466	Roles of Nuclear Receptors in Vascular Calcification. International Journal of Molecular Sciences, 2021, 22, 6491.	1.8	3
467	Vascular Calcification Mechanisms: Updates and Renewed Insight into Signaling Pathways Involved in High Phosphate-Mediated Vascular Smooth Muscle Cell Calcification. Biomedicines, 2021, 9, 804.	1.4	22
468	A critical review of chronic kidney disease as a risk factor for coronary artery disease. IJC Heart and Vasculature, 2021, 35, 100822.	0.6	5
469	Phosphate Balance and CKD–Mineral Bone Disease. Kidney International Reports, 2021, 6, 2049-2058.	0.4	22
470	Association Between Kidney Clearance of Secretory Solutes and Cardiovascular Events: The Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2021, 78, 226-235.e1.	2.1	7
471	Framing Cause-Effect Relationship of Acute Coronary Syndrome in Patients with Chronic Kidney Disease. Diagnostics, 2021, 11, 1518.	1.3	16
472	Insulin Resistance is Associated with Subclinical Vascular Injury in Patients with a Kidney Disease. Current Cardiology Reviews, 2021, 17, e160721189014.	0.6	0
473	Vascular Calcification in Chronic Kidney Disease. , 2009, , 697-711.		2
474	Cardiac disease in chronic uremia. , 2004, , 765-790.		3

#	Article	IF	CITATIONS
475	An In Vitro Murine Model of Vascular Smooth Muscle Cell Mineralization. Methods in Molecular Biology, 2016, 1397, 209-220.	0.4	7
476	Cardiovascular Aspects of Kidney Disease. , 2012, , 2059-2080.		5
478	Medical and revascularization management in acute coronary syndrome in renal patients. Seminars in Nephrology, 2001, 21, 25-35.	0.6	11
479	The impact of chronic kidney disease on long-term outcomes following semi-urgent and elective percutaneous coronary intervention. Coronary Artery Disease, 2021, 32, 517-525.	0.3	2
480	Darbepoetin Alpha Reduces Oxidative Stress and Chronic Inflammation in Atherosclerotic Lesions of Apo E Deficient Mice in Experimental Renal Failure. PLoS ONE, 2014, 9, e88601.	1.1	4
481	Carotid Atherosclerotic Disease Predicts Cardiovascular Events in Hemodialysis Patients: A Prospective Study. PLoS ONE, 2015, 10, e0127344.	1.1	13
482	Association between Density of Coronary Artery Calcification and Serum Magnesium Levels among Patients with Chronic Kidney Disease. PLoS ONE, 2016, 11, e0163673.	1.1	42
483	Effect of Bone Marrow-Derived Mesenchymal Stem Cells on Ischaemic-Reperfused Hearts in Adult Rats with Established Chronic Kidney Disease. International Journal of Stem Cells, 2019, 12, 304-314.	0.8	3
484	Comparison of Long-Term Clinical Outcome After Sirolimus-Eluting Stent Implantation in Patients With and Without Hemodialysis. International Heart Journal, 2007, 48, 689-700.	0.5	15
485	Coronary Heart Disease in Chronic Renal Insufficiency. Journal of the American Society of Nephrology: JASN, 2000, 11, 1948-1956.	3.0	30
486	Remodeling of Resistance Arteries in Renal Failure. Journal of the American Society of Nephrology: JASN, 2001, 12, 2040-2050.	3.0	26
487	Association of Elevated Serum PO4, Ca × PO4 Product, and Parathyroid Hormone with Cardiac Mortality Risk in Chronic Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2001, 12, 2131-2138.	3.0	1,037
488	Role of Calcium-Phosphate Product and Bone-Associated Proteins on Vascular Calcification in Renal Failure. Journal of the American Society of Nephrology: JASN, 2001, 12, 2511-2516.	3.0	160
489	Clinical Consequences and Novel Therapy of Hyperphosphatemia: Lanthanum Carbonate for Dialysis Patients. Recent Patents on Cardiovascular Drug Discovery, 2007, 2, 29-34.	1.5	7
490	Phosphate overload accelerates vascular aging in uremic patients. Heart International, 2006, 2, 6.	0.4	1
491	Renal Transplantation in Patients with Aortoiliac Prosthetic Grafts: A Case Report and Pertinent Review of Literature. Open Journal of Organ Transplant Surgery, 2015, 05, 1-5.	0.3	2
492	Peripheral artery calcifications evaluated by histology correlate to those detected by CT: relationships with fetuin-A and FGF-23. Journal of Nephrology, 2011, 24, 313-321.	0.9	34
493	Validation of a prognostic function for renal transplant recipients in Hungary. Journal of Nephrology, 2011, 24, 619-624.	0.9	1

#	ARTICLE	IF	CITATIONS
494	Cardiac valve calcification is a marker of vascular disease in prevalent hemodialysis patients. Journal of Nephrology, 2012, 25, 211-218.	0.9	34
495	Dyslipidemia, statins, and CKD patients' outcomes – review of the evidence in the post-sharp era. Journal of Nephrology, 2012, 25, 460-472.	0.9	16
496	Change in ankle-brachial index over time and mortality in diabetics with proteinuria. Clinical Nephrology, 2012, 78, 335-345.	0.4	5
497	Vascular calcification: When should we interfere in chronic kidney disease patients and how?. World Journal of Nephrology, 2016, 5, 398.	0.8	18
498	Renal Bone Diseases. , 2001, , 635-661.		1
499	Prevention, Diagnosis and Management of Heart Disease in Patients with Renal Failure. , 2002, , 129-145.		0
500	Treatment of renal bone disease. , 2004, , 279-294.		1
501	Hypertension in End-Stage Renal Disease. , 2004, , 389-402.		0
502	Acute coronary syndrome (ACS) in patients with chronic renal failure/hemodialysis. Journal of the Japanese Society of Intensive Care Medicine, 2006, 13, 417-422.	0.0	0
506	Lower level of fetuin-A concentrations related to the calcification and thickening of intima media of the carotid artery in hemodialysis patients. Nihon Toseki Igakkai Zasshi, 2010, 43, 443-452.	0.2	0
508	Chronic Kidney Disease-Mineral Bone Disorder. , 2011, , 2021-2058.		1
510	The Endothelium and Hemodialysis. , 0, , .		1
512	The New Kidney and Bone Disease: Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD). , 0, , .		1
513	Mineralized Blood Vessels in the Capsules of Human Pineal Glands. The Showa University Journal of Medical Sciences, 2013, 25, 249-254.	0.1	0
514	Clinical Implication of Vascular Calcification in Patients Undergoing Hemodialysis: The End or the Beginning of Disease. Korean Journal of Medicine, 2014, 87, 39.	0.1	0
515	CVD in CKD: Focus on the Dyslipidemia Problem. , 2014, , 67-91.		0
516	Vascular Calcification. , 2014, , 1-18.		0
517	Dyslipidemia in Dialysis. , 2014, , 179-202.		0

ARTICLE IF CITATIONS # Coronary Artery Disease in Patients with Chronic Kidney Disease - A Review. Cardiovascular Journal, 518 0.0 2 2011, 1, 97-104. Renal Bone Diseases., 1999, , 119-127. Vascular Access Calcification and Arteriovenous Fistula Maturation. The Open Urology & Nephrology 520 0.2 1 Journal, 2014, 7, 22-25. Chronic Kidney Disease and Renovascular Interactions., 2015, , 299-312. Vascular Calcification., 2015,, 327-341. 524 0 Role of Imaging in Chronic Kidney Disease., 2015, , 365-385. ASSOSIATION BETWEEN PARAMETERS OF MINERAL BONE METABOLISM AND SURVIVAL IN PATIENTS 526 0.0 0 UNDERGOING CHRONIC HEMODIALYSIS. Acta Medica Medianae, 2015, 54, 37-45. Impact of Abnormal Serum Electrolyte Levels and Acid-Base Disorders on Clinical Outcomes among 0.1 Maintenance Hemodialysis Patients. Open Access Library Journal (oalib), 2017, 04, 1-13. Revascularization Strategies in CKD: Antiplatelet Therapy, Stent Type, Timing, and Complications of PCI. 528 0 , 2017, , 329-335. Coronary Artery Disease in CKD: Traditional and Nontraditional Risk Factors, Diagnosis and 529 Management., 2017, , 35-43. The Impact of Arterial Micro-calcification of the Vascular Access on Coronary Artery Calcification and Cardiovascular Mortality in Incident Hemodialysis Patients. Korean Journal of Medicine, 2017, 92, 530 0.1 1 269-276. Chronic Kidney Disease-Mineral Bone Disease (CKD-MBD) and Cardiac Arrest Risk Factors among Renal Failure Patients. Journal of Applied Biotechnology & Bioengineering, 2017, 3, . Increase Renal CYP2C23 Expression Using Thiazide Diuretics Attenuate the Progression of 532 Cardiovascular Disease in Rat Model of Chronic Renal Failure. Medical Journal of the University of 0.0 0 Cairo Faculty of Medicine, 2018, 86, 2511-2519. Towards cardiovascular risks in children with chronic kidney disease: a prospective cohort study. 0.8 F1000Research, 0, 7, 1794. Altered lipid metabolism and serum lipids in chronic kidney disease., 2022, , 43-60. 534 2 Calcium, phosphate, PTH, vitamin D, and FGF-23 in CKD-mineral and bone disorder., 2022, , 353-381. 536 Maintenance Hemodialysis., 2020, , 259-281. 0 Hyperphosphatemia and vascular calcification in chronic kidney disease. Therapy: Open Access in Clinical Medicine, 2006, 3, 691-692.

#	Article	IF	CITATIONS
538	Skeletal and cardiovascular consequences of a positive calcium balance during hemodialysis. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2021, 43, 539-550.	0.4	3
540	Expression of Cyclophilin A in Coronary Artery Plaque with Intraplaque Hemorrhage Is More Frequent in Deceased Patients Who Had Impaired Kidney Function. International Heart Journal, 2020, 61, 1129-1134.	0.5	2
541	Kv1.3 Channel Inhibition Limits Uremia-Induced Calcification in Mouse and Human Vascular Smooth Muscle. Function, 2020, 2, zqaa036.	1.1	2
543	Relationship between Calcium-Phosphorus Product and Severity of Valvular Heart Insufficiency in Patients Undergoing Chronic Hemodialysis. The Journal of Tehran Heart Center, 2010, 5, 78-82.	0.3	2
544	Experimentally-Induced Metabolic Acidosis Does not Alter Aortic Fatty Streak Formation in High-Cholesterol Fed Rabbits. Iranian Journal of Basic Medical Sciences, 2012, 15, 1168-72.	1.0	1
545	Atherosclerosis Burden and Therapeutic Challenges Regarding Acute Coronary Syndromes in Chronic Kidney Disease Patients. Mædica, 2019, 14, 378-383.	0.4	1
546	Vascular Calcification in Chronic Kidney Disease: Distinct Features of Pathogenesis and Clinical Implication. Korean Circulation Journal, 2021, 51, 961.	0.7	17
547	Possible effect of dialysis membrane in polymethylmethacrylate on clinical variables associated with atherosclerosis development in chronic renal failure patients. Archives of Renal Diseases and Management, 2022, 7, 001-005.	0.3	0
548	Systematic review of the results of kidney transplantation in patients with aortoiliac revascularization surgery. Angiologia, 2022, , .	0.0	0
549	Kidney function and the risk of sudden cardiac death in the general population. CKJ: Clinical Kidney Journal, 2022, 15, 1524-1533.	1.4	4
550	Cardiac Biomarkers and Risk of Atherosclerotic Cardiovascular Disease in Patients with CKD. Kidney360, 2022, 3, 859-871.	0.9	6
551	Prevalence, predictors, and outcomes of in-stent restenosis with calcified nodules. EuroIntervention, 2022, 17, 1352-1361.	1.4	7
552	The Fundamental Role of Stress Echo in Evaluating Coronary Artery Disease in Specific Patient Populations. Current Vascular Pharmacology, 2022, 20, 156-167.	0.8	1
553	Uremic Toxins and Cardiovascular Risk in Chronic Kidney Disease: What Have We Learned Recently beyond the Past Findings?. Toxins, 2022, 14, 280.	1.5	20
555	Framingham and American College of Cardiology/American Heart Association Pooled Cohort Equations, Highâ€Sensitivity Troponin T, and Nâ€Terminal Pro–Brainâ€Type Natriuretic Peptide for Predicting Atherosclerotic Cardiovascular Events Across the Spectrum of Kidney Dysfunction. Journal of the American Heart Association, 2022, 11, .	1.6	5
556	Atherosclerotic plaque composition and specific endovascular considerations in the end stage renal disease patients: a narrative review. Cardiovascular Diagnosis and Therapy, 2021, .	0.7	0
557	A Associação de TWEAK com Calcificação da Artéria Coronária em Pacientes com Doença Renal Crônica. Arquivos Brasileiros De Cardiologia, 2022, , .	0.3	0
558	Doseâ€dependent effect of impaired renal function on all ause mortality in patients following percutaneous coronary intervention. Clinical Cardiology, 2022, 45, 882-891.	0.7	4

#	Article	IF	CITATIONS
560	Quantitative Data-Independent Acquisition Mass Spectrometry Proteomics and Weighted Correlation Network Analysis of Plasma Samples for the Discovery of Chronic Kidney Disease-Specific Atherosclerosis Risk Factors. DNA and Cell Biology, 0, , .	0.9	0
561	Longâ€ŧerm outcomes of intermediate coronary stenosis in patients undergoing hemodialysis after deferred revascularization based on fractional flow reserve. Catheterization and Cardiovascular Interventions, 2022, 100, 971-978.	0.7	3
562	From <scp>MIA</scp> to <scp>FIFA</scp> : The vicious matrix of frailty, inflammation, fluid overload and atherosclerosis in peritoneal dialysis. Nephrology, 2023, 28, 215-226.	0.7	3
564	Cardiovascular Calcification Heterogeneity in Chronic Kidney Disease. Circulation Research, 2023, 132, 993-1012.	2.0	18